Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?The Motley Fool • 10/03/26
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/01/26
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue ScaleThe Motley Fool • 10/01/26
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care MovementBusiness Wire • 10/01/26
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb's CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*Business Wire • 09/30/26
Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric24/7 Wall Street • 09/30/26
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to KnowZacks Investment Research • 09/30/26
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/29/26
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, MerckInvestors Business Daily • 09/29/26
Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogsSeeking Alpha • 09/26/26
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple MyelomaBusiness Wire • 09/25/26
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?Zacks Investment Research • 09/24/26
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?The Motley Fool • 09/24/26
4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout24/7 Wall Street • 09/23/26
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-TermZacks Investment Research • 09/21/26